Research programme: amyotrophic lateral sclerosis gene therapy - Gene Therapy Research Institution

Drug Profile

Research programme: amyotrophic lateral sclerosis gene therapy - Gene Therapy Research Institution

Latest Information Update: 14 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Gene Therapy Research Institution
  • Class
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Amyotrophic lateral sclerosis

Most Recent Events

  • 11 Aug 2017 Preclinical trials in Amyotrophic lateral sclerosis in Japan (IV) (Gene Therapy Research Institution pipeline, August 2017)
  • 11 Aug 2017 Pharmacodynamics and adverse events data from a preclinical study in Amyotrophic lateral sclerosis released by Gene Therapy Research Institution (Gene Therapy Research Institution website, August 2017)
  • 11 Aug 2017 Gene Therapy Research Institution plans phase I/II trials in 2019 (Gene Therapy Research Institution pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top